State Medical Board Considering New Rules for Anorexiants

Posted Date: May 27th, 2014 | Categories: Health Care & Businesses

The State Medical Board of Ohio is considering adopting a new rule applicable to prescribing controlled substance anorexiants with approved FDA labeling for chronic weight management. Currently, the only FDA approved drugs are marketed under the brand names of Qysmia® and Belviq®. The proposed new rule (OAC: 4731-11-04.1) requires that a physician determine whether to initiate treatment after performing an assessment of the patient and screening for contraindications; requires the drug be prescribed in strict compliance with FDA approved labeling; requires the physician to meet face-to-face with the patient for the initial visit and two follow-up visits; authorizes the physician, after the second follow-up visit, to write for refills or to authorize a physician assistant to provide the treatment; requires specific supervising physician oversight when treatment is provided by a physician assistant; and requires the physician and physician assistant to comply with the rules concerning the utilization of OARRS. The Jones Law group and the OOA will be submitting comments on the initial draft by the June 6 deadline.

Leave a Reply

Your email address will not be published. Required fields are marked *


Please enter the CAPTCHA text

call Columbus Attorney
Call for a free Consultation


Email us now!